Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXHealthcare · Biotechnology
+0.63%$28.86
AH$28.86+0.00%vs close
Mkt Cap$3.62B
Float96.37M
O/S125.51M
Vol
$ Vol
RVOL
Inst Own91.7%
SI13.8%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$144.74M
Total Assets$332.64M
Free Cash Flow-$123.48M
Debt & Equity
Debt 2%
Equity 98%
Total Debt$5.96M
Total Equity$305.26M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in AMLX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$332.64M
Liabilities$27.39M
Accounts Receivable$88K
Accounts Payable$3.52M
Inventory$0
PP&E (Net)$5.49M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $87.37M | $380.79M | $22.23M | $0 | $650K | $1.43M |
| YoY Growth | - | -77.1% | 1612.9% | - | - | -54.4% | - |
| Cost of Revenue | $525K | $42.16M | $25.44M | $2.99M | $0 | $24.59M | $11.9M |
| Gross Profit | -$525K | $45.22M | $355.35M | $19.24M | $0 | -$23.94M | -$10.47M |
| Gross Margin | - | 51.8% | 93.3% | 86.5% | - | -3683.7% | -734.4% |
| Research and Development | $90.4M | $104.08M | $128.19M | $93.45M | $44.04M | $24.59M | $11.9M |
| Selling, General, and Administrative | $62.89M | $114.33M | $188.36M | $127.13M | $38.93M | $15.06M | $3.08M |
| Other | $0 | $141.53M | $0 | $0 | -$285K | -$24.59M | -$1.43M |
| Total Operating Expenses | $152.77M | $359.95M | $316.54M | $220.58M | $82.69M | $15.06M | $13.55M |
| Operating Income (EBIT) | -$153.29M | -$314.73M | $38.8M | -$201.34M | -$82.69M | -$39.01M | -$13.55M |
| Operating Margin | - | -360.2% | 10.2% | -905.7% | - | -6000.8% | -950.5% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $2.29M | $1.28M |
| Interest Income | $9.3M | $13.81M | $16.16M | $4.29M | $36K | $14K | $176K |
| Other Income (Expense) | $8.6M | $12.6M | $15.49M | $3.74M | -$5.24M | -$3.27M | -$162K |
| Income Before Tax (EBT) | -$144.69M | -$302.14M | $54.3M | -$197.6M | -$87.93M | -$42.28M | -$13.72M |
| Income Tax Expense | $46K | -$393K | $5.03M | $774K | $0 | $0 | $0 |
| Net Income | -$144.74M | -$301.74M | $49.27M | -$198.38M | -$87.93M | -$42.28M | -$14.82M |
| Net Income Margin | - | -345.4% | 12.9% | -892.4% | - | -6504.6% | -1039.0% |
| Supplementary Data | |||||||
| EPS | -1.53 | -4.43 | 0.73 | -2.98 | -1.52 | -0.79 | -0.26 |
| Diluted EPS | -1.53 | -4.43 | 0.70 | -2.98 | -1.52 | -0.79 | -0.26 |
| Weighted Average OS | 94.57M | 68.14M | 67.23M | 66.51M | 57.86M | 56.47M | 56.47M |
| EBITDA | -$144.16M | -$290.98M | $55.38M | -$197.11M | -$87.88M | -$39M | $1.11M |
| EBITDA Margin | - | -333.0% | 14.5% | -886.7% | - | -6000.6% | 78.1% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $226.65M | $77.39M | $170.2M | $62.53M | $50.19M | $12.88M | $3.06M |
| Short-Term Investments | $90.33M | $99.11M | $201.16M | $284.42M | $45.93M | $0 | $0 |
| Cash and Short-Term Investments | $316.98M | $176.5M | $371.36M | $346.94M | $96.12M | $12.88M | $3.06M |
| Accounts Receivable | $88K | $447K | $40.05M | $15.31M | $0 | $0 | $0 |
| Inventory | $0 | $0 | $38.32M | $9.77M | $0 | $0 | $0 |
| Other Current Assets | $6.6M | $12.48M | $14.93M | $10.11M | $3.44M | $0 | $26K |
| Total Current Assets | $323.67M | $189.43M | $464.67M | $382.13M | $104.95M | $13.64M | $3.2M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $5.49M | $2.73M | $6.41M | $8.13M | $474K | $151K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $189K | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $3.48M | $1.47M | $46.38M | $1.19M | $189K | $125K | $18K |
| Total Long-Term Assets | $8.97M | $4.2M | $52.79M | $9.32M | $663K | $465K | $18K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $332.64M | $193.63M | $517.45M | $391.45M | $105.61M | $14.1M | $3.22M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $3.52M | $2.94M | $22.06M | $6.26M | $4.37M | $3.61M | $2.19M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $10.05M | $9.99M | $40.93M | $15.23M | $4.28M | $0 | $652K |
| Total Current Liabilities | $22.69M | $28.41M | $82.04M | $46.61M | $17.4M | $7.33M | $4.53M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $4.7M | $0 | $0 | $0 | $0 | $1.43M | $14.93M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $14K | $4K |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $239.39M | $72.06M | $9.11M |
| Total Long-Term Liabilities | $4.7M | $463K | $1.98M | $4.24M | $239.39M | $73.5M | $24.05M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $27.39M | $28.87M | $84.02M | $50.85M | $256.78M | $80.83M | $28.58M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $72.06M | $0 |
| Common Stock | $11K | $7K | $7K | $7K | $1K | $1K | $1K |
| Retained Earnings | -$751.43M | -$606.69M | -$304.95M | -$354.22M | -$155.84M | -$67.91M | -$25.63M |
| Comprehensive Income & Other | $404K | -$92K | $197K | -$86K | $9K | -$72.06M | $0 |
| Other Stockholders' Equity | $1.06B | $771.45M | $738.37M | $694.82M | $4.68M | $1.19M | $276K |
| Total Equity | $305.26M | $164.76M | $433.43M | $340.61M | -$151.17M | -$66.72M | -$25.36M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $332.64M | $193.63M | $517.45M | $391.45M | $105.61M | $14.1M | $3.22M |
| Supplementary Data | |||||||
| Total Debt | $5.96M | $1.98M | $4.24M | $6.28M | $0 | $1.43M | $14.93M |
| Net Debt | -$220.69M | -$75.41M | -$165.96M | -$56.25M | -$50.19M | -$11.45M | $11.87M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$144.74M | -$301.74M | $49.27M | -$198.38M | -$87.93M | -$42.28M | -$13.72M |
| Depreciation & Amortization | $525K | $904K | $1.09M | $487K | $52K | $1K | $13.55M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $27.64M | $33.04M | $37.16M | $21.71M | $3.14M | $243K | $108K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $383K | $39.6M | -$24.74M | -$15.31M | -$144K | $0 | $0 |
| Inventory | $0 | -$9.25M | -$73.13M | -$9.77M | $0 | $0 | $0 |
| Accounts Payable | $580K | -$19.1M | $15.88M | $1.85M | $670K | $1.42M | $1.28M |
| Other Working Capital | -$2.05M | -$57.08M | $16.33M | $21.58M | $4.07M | $1.18M | $2.22M |
| Total Working Capital Change | -$1.08M | -$45.83M | -$65.66M | -$1.64M | $4.59M | $2.6M | $3.5M |
| Other Non-Cash Items | -$5.7M | $145.99M | -$9.94M | -$2.06M | $5.35M | $2.74M | -$14.14M |
| Net Cash from Operating | -$123.34M | -$167.65M | $11.92M | -$179.87M | -$74.8M | -$36.7M | -$10.69M |
| Investing Activities | |||||||
| Capital Expenditures | -$138K | -$157K | -$1.24M | -$2.53M | -$353K | -$151K | $0 |
| Acquisitions | $0 | $0 | $0 | $236.46M | $0 | $0 | $0 |
| Purchases of Investments | -$231.82M | -$231.99M | -$300.83M | -$415.87M | -$49.05M | $0 | $0 |
| Sales of Investments | $246M | $344M | $394.12M | $179.41M | $3M | $0 | $0 |
| Other Investing Activities | $0 | -$36.2M | $0 | -$236.46M | $0 | $0 | $0 |
| Net Cash from Investing | $14.04M | $75.65M | $92.05M | -$238.99M | -$46.41M | -$151K | $0 |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | -$25.9M | -$16.82M | -$641K |
| Common Stock Issuance | $260.39M | $2.13M | $6.86M | $432.45M | $0 | $0 | $27K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$3.36M | -$1.78M | -$3.31M | -$658K | -$2.39M | $48K | $0 |
| Net Cash from Financing | $257.03M | $348K | $3.54M | $431.79M | $158.51M | $46.82M | $668K |
| Forex Effect | $1.07M | -$438K | $160K | -$65K | $13K | $0 | $13.11M |
| Net Change in Cash | $148.8M | -$92.08M | $107.67M | $12.87M | $37.31M | $9.97M | $3.09M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$123.34M | -$167.65M | $11.92M | -$179.87M | -$74.8M | -$36.7M | -$10.69M |
| Capital Expenditure | -$138K | -$157K | -$1.24M | -$2.53M | -$353K | -$151K | $0 |
| Free Cash Flow | -$123.48M | -$167.8M | $10.68M | -$182.4M | -$75.15M | -$36.85M | -$10.69M |
| Cash at Beginning | $78.84M | $170.92M | $62.53M | $50.38M | $13.07M | $3.09M | $0 |
| Cash at End | $227.64M | $78.84M | $170.2M | $63.24M | $50.38M | $13.07M | $3.09M |